Serial 99211010

Live / Applied — First extension granted (statement of use) (as of 25 Mar 2026)

What this means for you

Not registered yet, but its 30 May 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
99211010
Mark type
Design / logo
Filed
30 May 2025
Published for opposition
16 Sept 2025
Attorney of record
Aaron D. Hendelman

Goods and services

  • Class 005 — Pharmaceuticals: Therapeutic pharmaceuticals in the nature of oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of and prevention of musculoskeletal, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, and muscle atrophy related diseases and disorders; pharmaceutical preparations for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; therapeutic pharmaceutical for the treatment and prevention of viral, metabolic, endocrine, musculoskeletal, autoimmune, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, neurodegenerative, gastrointestinal, hormonal, dermatological, psychiatric, genetic, and immune system related diseases and disorders; therapeutic pharmaceuticals for the treatment and prevention of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes
  • Class 040 — Treatment of materials: Custom manufacturing of oligonucleotide-conjugate based pharmaceutical therapies, oligonucleotide-antibody conjugate based pharmaceutical therapies, and oligonucleotide-antibody fragment conjugate based pharmaceutical therapies; custom manufacturing of pharmaceuticals; contract manufacturing in the field of pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing
  • Class 042 — Scientific and technological services: Medical and scientific research, namely, conducting clinical trials for others; providing medical and scientific research information in the fields of pharmaceuticals, biotechnology, and clinical trials; pharmaceutical research and development; pharmaceutical products development; research and development in the field of biotechnology; providing medical and scientific research information in the fields of pharmaceuticals, therapeutics, medicines and vaccines
  • Class 044 — Medical, beauty and agricultural services: Providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceuticals, therapeutics, medicines, and vaccines, and medical information in the fields of healthcare, health conditions, health awareness and treatment options; medical information services, namely, providing information related to healthcare, diseases, disorders, and treatment options; online medical information services, namely, providing a website related to healthcare, health awareness, diseases, disorders, treatment options, and the diagnostic, prophylactic and therapeutic properties of medicines and vaccines

Owner

Prosecution history

  • 26 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 25 Mar 2026 — SOU EXTENSION 1 GRANTED
  • 25 Mar 2026 — SOU EXTENSION 1 FILED
  • 25 Mar 2026 — SOU TEAS EXTENSION RECEIVED
  • 05 Mar 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 05 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
  • 05 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
  • 05 Mar 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
  • 05 Mar 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
  • 11 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 16 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 16 Sept 2025 — PUBLISHED FOR OPPOSITION
  • 10 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 05 Sept 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
  • 05 Sept 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

View this trademark record on Marksy